A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2014
At a glance
- Drugs Eribulin (Primary) ; Ixabepilone
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Eisai Inc; Eisai Medical Research
- 22 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Sep 2012 Results presented at the 2012 Breast Cancer Symposium.
- 06 Sep 2012 Planned end date changed from 1 Feb 2011 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History